Dosage Form
Lyophilized Product CDMOs
Compare CDMOs manufacturing lyophilized drug products for biologics, peptides, and injectable pharmaceuticals. Filter by dryer capacity, cycle development expertise, and scale.
128 companies listed
About Lyophilized Product Manufacturing
Lyophilized (freeze-dried) products are manufactured by removing water from a drug formulation through sublimation, producing a stable dry cake that is reconstituted before use. This dosage form is essential for biologics, peptides, and other molecules that are unstable in liquid form. The lyophilization process occurs after aseptic vial filling, making it an integrated part of the sterile manufacturing process.
Key CDMO selection criteria for lyophilized products include: cycle development expertise (thermal analysis, process optimization), dryer capacity (shelf area determines batch size), scale-up capability (lab to commercial dryers), and integrated fill-finish services. CDMOs offering end-to-end fill-lyophilize-inspect services eliminate the logistics complexity of shipping partially stoppered vials between facilities.
Companies (128)
JCR Pharmaceuticals
Japan
JCR Pharmaceuticals is a Japanese pharmaceutical company and CDMO founded in 1975, with nearly 50 years of experience in rare disease treatments and orphan drug production. Selected for Japan's Regenerative Medicine CDMO Subsidy Program in 2025, the company is expanding biomanufacturing infrastructure for cell, gene, and regenerative medicine therapies. JCR operates five production sites and has proprietary platforms including JUST-AAV for gene therapy and J-Brain Cargo for blood-brain barrier penetration.
Biologics Drug SubstanceBiologics Drug ProductBiologics Manufacturing
Liof Pharma
Spain
Liof Pharma is a European CDMO headquartered in the Basque Country, Spain, specializing in aseptic manufacturing and lyophilization of sterile injectable biologics. With over 15 years of experience, the company provides clinical and commercial manufacturing of biologics drug products including monoclonal antibodies, peptides, proteins, mRNA, AAV viral vectors, and vaccines. The facility operates in compliance with EMA, FDA, ANVISA, and AEMPS regulations.
Frequently Asked Questions
What products are typically lyophilized?+
Common lyophilized products include: monoclonal antibodies (when liquid formulation stability is insufficient), vaccines, peptide and protein therapeutics, oligonucleotide drugs, certain antibiotics (e.g., vancomycin), and diagnostic reagents. The decision to lyophilize depends on the product's liquid stability, target shelf life, and cold chain requirements.
What is the typical lyophilization cycle time?+
Cycle times vary significantly by product: simple small molecule formulations may lyophilize in 24-48 hours, while complex biologics can require 72-120 hours. Cycle optimization by an experienced CDMO can reduce these times by 20-40% while maintaining product quality. The total vial processing time (fill through lyophilization through stoppering and crimping) is typically 4-7 days per batch.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
